An Industry Perspective on the Erice Declaration and Risk Minimisation Plans

Author： Ingate Simon   Tranter Deborah   Banerjee Anjan   Hobbs Andrew  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.29, Iss.8, 2006-01, pp. : 733-734

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Erice Declaration: The Critical Role of Communication in Drug Safety

By Hugman Bruce  

Drug Safety, Vol. 29, Iss. 1, 2006-01 ,pp. : 91-93

Adis International

Access to resources Recommend Favorite

Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective

By Bwire Robert   Freeman John   Houn Florence  

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 3-8

Informa Healthcare

Access to resources Recommend Favorite

Risk-minimisation measures implemented for dosulepin

By  

Reactions Weekly, Vol. 1, Iss. 1182, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The Art and Science of Risk Management: A US Research-Based Industry Perspective

By Janice K. Bush  

Drug Safety, Vol. 28, Iss. 1, 2005-01 ,pp. : 1-18

Adis International

Access to resources Recommend Favorite

Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed

By Nicholson Susan   Peterson Janet   Yektashenas Behin  

Expert Opinion on Drug Safety, Vol. 11, Iss. 2, 2012-03 ,pp. : 299-314

Informa Healthcare

Access to resources Recommend Favorite